Noggin Blocker Bone Grafts Reduce BMP Dosage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone grafting methods, particularly those using synthetic bone grafts, face challenges such as high costs and the need for high concentrations of bone morphogenetic proteins (BMPs) like BMP-2, which limits their routine clinical use, and complications associated with harvesting bone from donor sites like the iliac crest.
Innovation Solution
Development of bone graft compositions comprising substituted 3-phenyl-2-(pyridin-2-yl)acrylonitrile derivatives or their salts, combined with a graft matrix, which can resist the degrading effects of Noggin, potentially reducing the need for BMPs by enhancing bone growth through Noggin blockers and inclusion of BMPs like BMP-2 or BMP-7, along with calcium phosphates and other osteogenic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of BMP-2 are used in synthetic bone grafts, then bone formation capability is improved, but cost and treatment complexity increase
Solution Approach 1:
The patent introduces Noggin-blocking compounds as intermediary substances that mediate between BMP-2 and its receptors. These compounds block Noggin's inhibitory action, thereby enhancing BMP-2's osteogenic effect at lower concentrations. The intermediary substance acts as a molecular bridge to overcome the natural inhibition without requiring high doses of BMP-2
Solution Approach 2:
The patent changes the biochemical parameters of the bone graft system by adding Noggin-blocking compounds. This parameter change (blocking the Noggin inhibitor) allows for reduced BMP-2 concentration while maintaining or enhancing bone formation capability, thus resolving the contradiction between effectiveness and complexity
2Reliability
If Noggin-blocking compounds are added to bone graft compositions, then BMP activity is enhanced, but composition complexity increases
Solution Approach 1:
The patent merges multiple functional components into a single integrated bone graft composition. The Noggin-blocking compound, BMP-2, and graft matrix are combined into one formulation that works synergistically. This merging approach enhances BMP activity while managing composition complexity through integrated design rather than separate components
3Reliability
If autologous bone grafting is performed, then bone formation quality is improved, but donor site complications increase
Solution Approach 1:
The patent replaces the need for harvesting expensive and problematic autologous bone with synthetic bone graft compositions. The synthetic graft acts as a disposable alternative that eliminates donor site trauma while providing sufficient bone formation capability through the Noggin-blocking mechanism
Solution Approach 2:
The Noggin-blocking compound serves as an intermediary that enables synthetic materials to achieve bone formation quality previously only attainable through autologous grafts, by enhancing the osteogenic signal without requiring harvested bone
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a Noggin blocker.